The significant outperformance of Apellis Pharmaceuticals over the past 5 years, as indicated by its 36.05% annualized return and the growth of a $100 investment to $451.80, suggests a strong positive sentiment and robust financial health. This historical performance, coupled with a substantial market capitalization of $8.01 billion, is likely to instill confidence in investors, potentially leading to a short-term positive impact on the stock price.